Fintel reports that on August 7, 2023, Barclays maintained coverage of Amneal Pharmaceuticals Inc - (NYSE:AMRX) with a Overweight recommendation.
Analyst Price Forecast Suggests 13.14% Downside
As of August 2, 2023, the average one-year price target for Amneal Pharmaceuticals Inc - is 3.57. The forecasts range from a low of 3.03 to a high of $4.20. The average price target represents a decrease of 13.14% from its latest reported closing price of 4.11.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Amneal Pharmaceuticals Inc - is 2,355MM, an increase of 1.86%. The projected annual non-GAAP EPS is 0.79.
What is the Fund Sentiment?
There are 314 funds or institutions reporting positions in Amneal Pharmaceuticals Inc -. This is a decrease of 22 owner(s) or 6.55% in the last quarter. Average portfolio weight of all funds dedicated to AMRX is 0.03%, an increase of 6.54%. Total shares owned by institutions decreased in the last three months by 7.73% to 102,084K shares. 
The put/call ratio of AMRX is 0.09, indicating a bullish outlook.
What are Other Shareholders Doing?
Fosun International holds 21,521K shares representing 14.04% ownership of the company. No change in the last quarter.
Tpg Gp A holds 12,329K shares representing 8.04% ownership of the company. No change in the last quarter.
Eversept Partners holds 5,183K shares representing 3.38% ownership of the company. In it's prior filing, the firm reported owning 831K shares, representing an increase of 83.97%. The firm increased its portfolio allocation in AMRX by 311.23% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,990K shares representing 2.60% ownership of the company. No change in the last quarter.
Neuberger Berman Group holds 3,683K shares representing 2.40% ownership of the company. In it's prior filing, the firm reported owning 3,490K shares, representing an increase of 5.24%. The firm decreased its portfolio allocation in AMRX by 64.46% over the last quarter.
Amneal Pharmaceuticals Background Information
(This description is provided by the company.)
Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.
Additional reading:
- AMNEAL REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS ‒ Q2 2023 Net Revenue of $599 million; GAAP Net Income of $12 million; Diluted EPS of $0.08 ‒ ‒ Q2 2023 Adjusted Net Income(1) of $57 million; Adjusted EBITDA (1) of $146 million; Adjusted Diluted
- IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE RUSSELL THIELE and JEFFREY ) EDELMAN, Derivatively on Behalf of ) AMNEAL PHARMACEUTICALS, ) INC., ) Plaintiffs, ) ) v. ) C.A. No. 2022-0272-LWW ) KASHIV BIOSCIENCES, LLC, ) CHINTU PATEL, CHIRAG PATEL,
- by and among Amneal Pharmaceuticals, Inc. and
- by and among Amneal Pharmaceuticals, Inc. and
- Modification No. 2 to Employment Agreement, dated February
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
